As in the previous year, EANpages asked EAN committee members, panel chairs, and invited speakers which session one should not miss at the upcoming congress in Amsterdam 2017. Please find their answers below!
Tag
dementia
-
-
by Anna Sauerbier Research and Innovation performance and Horizon 2020 country participation
http://ec.europa.eu/programmes/horizon2020/en/news/research-and-innovation-performance-and-horizon-2020-country-participation Health at a Glance: Chronic disease costs European economy €115B a year
http://sciencebusiness.net/health/news/2016/health-at-a-glance-chronic-disease-costs-european-economy-115b-a-year/ Public-private European partnership (ROADMAP) paves the way for sustainable platform for the generation… Continue Reading -
Executive PageFeatured Slider
President’s Page: Treatment of neurodegenerative diseases: are we close to a breakthrough?
October 1, 2016It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimer’s and Parkinson’s disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD (1) and AD (2) communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community. -
By Anna Sauerbier New understanding of how Alzheimer’s develops https://erc.europa.eu/projects-and-results/erc-stories/new-understanding-how-alzheimers-develops Air pollutants strongly linked to Alzheimer’s http://www.euractiv.com/section/health-consumers/news/air-pollutants-strongly-linked-to-alzheimers/ MODEM modelling outcome and cost impacts of interventions for dementia http://www.modem-dementia.org.uk/ The Human Brain Project and the… Continue Reading
-
Paper of the MonthFeatured Slider
Paper of the month and Scientific Debate: A new hope for Alzheimer’s disease treatment with the PRIME study?
October 1, 2016For October 2016 we have selected: Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50-56. Alzheimer’s disease (AD) is the most frequent neurodegenerative disorder. It is also extremely disabling with severe impact of the quality of life of patients and caregivers. The main pathological process is related to the toxic deposition of amyloid-β plaques and neurofibrillary tangles. No effective treatment is currently available to slow down the disease progression. -
Scientific CornerFeatured Slider
A ROUND TABLE discussion of the Paper of the Month with the EAN SCIENTIFIC PANEL on DEMENTIA AND COGNITIVE DISORDERS
October 1, 2016EANpages has the honor and the pleasure to introduce this virtual Round Table, composed by some members of the EAN Scientific Panel on Dementia and Cognitive Disorders, who are discussing the Paper of the Month, in addition to the comments of the Presidential Page. We thank the Panel for their enthusiastic participation and we invite all EAN members to participate with sending their comments. -
EAN Congress news
Copenhagen 2016: Report of Plenary Symposium 2 – Neuroimaging of dementia
May 30, 2016Plenary Symposium 2
Neuroimaging of dementia
Hall A, Mon, 2016-05-30, 10.30-12.30 Chairpersons:
Reinhold Schmidt, Graz, Austria.
Massimo Filippi, Milano, Italy. Imaging of cerebral small vessel disease
Reinhold Schmidt, Graz, Austria. Imaging of Alzheimer’s disease
Philip Scheltens, Amsterdam, The Netherlands. Imaging… Continue Reading -
This networking event was attended by about 60 people, mostly women from different countries but also by several men. It was a very inspiring session, in which three successful women shared their professional and personal experience as neurologists. Prof. N.… Continue Reading
-
Interviews
Interview with Prof. Sandro Sorbi incoming co-chair of the EAN Scientific Panel “Dementia and cognitive disorders”
May 4, 2016Elena Moro (EM): As incoming co-chair of the Scientific Panel “Dementia and cognitive disorders” can you briefly introduce yourself and your specific field of expertise to the EANpages readers? Sandro Sorbi (SS): I am a neurologist and psychiatrist by training, professor of Neurology and Chair of the First Neurology Clinic University of Florence, Careggi Hospital, Florence, and the scientific coordinator of the IRCSS Don Gnocchi, Florence, Italy. -
By Anna Sauerbier Dear Readers, please find here some related articles that might be of interest to you: Promising early trials in mice: Injections of a natural protein may lessen the symptoms and progress of… Continue Reading
-
Dear Readers, We invite you to read the following article recommendations, prepared for you by our Scientific Panels: Dementia and cognitive disorders, Higher cortical functions, Infectious diseases, Movement disorders, Palliative care. Winblad B, Amouyel P, Andrieu S, et al. Defeating… Continue Reading
-
As in the previous year, Neuropenews asked EAN committee members, panel chairs, speakers etc. which session one should not miss at the upcoming congress in Copenhagen 2016. Please find their answers below!
-
Forum
Neurological News from Denmark V – the land of the 2nd EAN congress 2016: Clinical Dementia Research in Denmark
March 1, 2016Since the establishments of the first multidisciplinary memory clinics, based in neurology in Denmark more than 20 years ago, neurologists have taken increasing interest in diagnostic evaluation and follow-up of patients with dementia. -
by David B. Vodusek and Eveline Sipido The neurological societies of the Maghreb held their 10th Congress in Tunis, Tunisia from December 3 – 5, 2015.
Prof. Riadh Gouider, President of the Tunisian Society of Neurology hosted the meeting. More… Continue Reading -
All e-learning activities are free-of-charge for EAN registered users. Answer all questions correctly and you will receive one hour of CME. European Journal of Neurology
Every month one article is chosen for online learning. The following articles are available free… Continue Reading